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Abstract
Aims Gestational diabetes (GDM) affects a growing number of women and identification of individuals at risk, e.g., with 
risk prediction models, would be important. However, the performance of GDM risk scores has not been optimal. Here, we 
assess the impact of GDM heterogeneity on the performance of two top-rated GDM risk scores.
Methods This is a substudy of the RADIEL trial—a lifestyle intervention study including women at high GDM risk. We 
assessed the GDM risk score by Teede and that developed by Van Leeuwen in our high-risk cohort of 510 women. To inves-
tigate the heterogeneity of GDM, we further divided the women according to GDM history, BMI, and parity. With the goal 
of identifying novel predictors of GDM, we further analyzed 319 women with normal glucose tolerance in the first trimester.
Results Both risk scores underestimated GDM incidence in our high-risk cohort. Among women with a BMI ≥ 30 kg/m2 
and/or previous GDM, 49.4% developed GDM and 37.4% received the diagnosis already in the first trimester. Van Leeuwen 
score estimated a 19% probability of GDM and Teede succeeded in risk identification in 61%. The lowest performance of 
the risk scores was seen among the non-obese women. Fasting plasma glucose,  HbA1c, and family history of diabetes were 
predictors of GDM in the total study population. Analysis of subgroups did not provide any further information.
Conclusions Our findings suggest that the marked heterogeneity of GDM challenges the development of risk scores for 
detection of GDM.
Keywords Gestational diabetes · Pregnancy · Prediction of diabetes · Screening · Obesity · Heterogeneity
Introduction
The global epidemic of diabetes is leading to expanding 
health care costs as well as an increased burden for the 
affected individuals. Preventive measures are, therefore, 
essential. Lifestyle intervention trials have shown that type 
2 diabetes [1, 2] and gestational diabetes (GDM) [3] can 
be prevented in high-risk groups, although the results have 
not been entirely consistent. Individualized interventions, 
however, are expensive, and therefore, a targeted interven-
tion focusing on those at highest risk would be most feasi-
ble. To identify individuals at increased risk, the European 
Evidence-Based Medicine Guidelines (EBMG) [4] and the 
International Diabetes Federation [5] recommend using a 
risk score.
Risk scores can successfully identify individuals at 
increased risk for type 2 diabetes [6], and this has encour-
aged development of GDM risk scores as well. A recent 
review [7] validated 12 published GDM risk scores. The 
most common predictors were age, adiposity, ethnicity, 
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family history of diabetes, history of GDM, and history of 
macrosomia. Score performance was, however, only moder-
ate, and the authors requested more research before imple-
menting GDM risk scores into practice.
Heterogeneity of type 2 diabetes is acknowledged [8, 9], 
but for GDM, it remains less well studied. We have previ-
ously shown that there is marked heterogeneity among GDM 
women [10]. Surprisingly, in the RADIEL study, the high-
est incidence of GDM was seen among non-obese women 
with a history of GDM; this despite showing no metabolic 
disturbances or diabetes-related autoantibodies during the 
first trimester. This might be suggestive of diverse patho-
physiology. Some studies have identified subgroups of GDM 
women with various degrees of impairment in insulin secre-
tion and sensitivity and presence of autoantibodies [11–13].
The aim of this study was to assess the heterogeneity 
of GDM and its influence on the moderate performance of 
GDM risk scores. We tested the two best-performing GDM 




This is a secondary analysis of the RADIEL study (The Finn-
ish GDM Prevention Study 2008–2014), conducted in the 
maternity hospitals of Helsinki (Helsinki University Hospi-
tal, HUH), and the South Karelia Central Hospital (SKCH) 
in Lappeenranta. The original study randomly assigned the 
participants into intervention and control groups, but in this 
study, they were combined as a cohort of women at high 
GDM risk. The RADIEL study has been described in detail 
previously [14].
Participants
Women at high GDM risk (BMI ≥ 30 kg/m2 and/or previous 
GDM) entered the study voluntarily either in pre-pregnancy 
or in early pregnancy before 20 gestational weeks. The 
exclusion criteria included overt diabetes, multiple preg-
nancy, physical disability, substance abuse, severe psychi-
atric disorders, difficulties in co-operation, and medication 
influencing glucose metabolism. All participants provided 
written informed consent, and the Ethics Committees of 
HUH and SKCH approved the protocol. Participants with 
a normal oral glucose tolerance test (OGTT) in the first 
trimester served as the focus group when assessing GDM 
predictors.
To assess the heterogeneity of GDM we divided the 
women into four groups (A, B, C, D) according to their 
pre-pregnancy BMI, parity, and history of GDM, similar to 
our previous studies [10, 15]. Group A: obese primiparous 
women, group B: multiparous obese women without GDM 
history, group C: multiparous non-obese women with pre-
vious GDM, and group D: multiparous obese women with 
previous GDM.
Outcome and predictor assessment
The primary study outcome was GDM incidence. At enroll-
ment (pre-pregnancy participants) as well as in the first (on 
average 13 gestational weeks) and in the second trimes-
ter (24–28 gestational weeks), all participants underwent 
a 75-g 2-h OGTT with diagnostic thresholds (at 0, 1, and 
2 h) of 5.3–10.0–8.6 mmol/l. Predictor assessment included 
anthropometrics, medical history, and laboratory tests. In the 
beginning of the study, questionnaires covered family his-
tory of diabetes and cardiovascular diseases, regular medica-
tions, and chronic illnesses. History of macrosomia was self-
reported, but hospital records provided verification for GDM 
history. Physical activity was self-reported as time per week 
spent in moderately strenuous activity. Food diaries and food 
frequency questionnaires provided data on dietary habits and 
were the base for calculating a dietary index, Healthy Food 
Intake Index (HFII), with higher scores indicating better 
adherence to the dietary recommendations [16].
Each visit included measurements of weight, waist, and 
hip circumference (non-pregnant participants), as well as 
blood pressure, measured from the right arm, in the sitting 
position, with a sphygmomanometer. Gestational weight 
gain (GWG) was the difference between pre-pregnancy 
weight (self-reported) and weight at the second trimester 
at 23.1 (median, IQR 22.4–24.1) gestational weeks. Gly-
cated hemoglobin  (HbA1C), fasting plasma insulin (fP-insu), 
total cholesterol (fP-Kol), low-density lipoprotein (fP-LDL) 
and high-density lipoprotein (fP-HDL) cholesterol, and tri-
glycerides (fP-trigly) from venous blood served as mark-
ers for lipid and glucose metabolism. Analysis additionally 
included adiponectin, interleukin-6 (IL-6), high-sensitivity 
C-reactive protein (hs-CRP), alanine aminotransferase 
(ALT), thyroid-stimulating hormone (TSH), and free thyrox-
ine (fT4). HOMA-IR, estimating insulin resistance, was cal-
culated by (FPI (mU/l) × FPG (mmol/l))/22.5, and HOMA-β, 
describing β-cell function, derived from formula (20 × FPI 
(mU/l))/(FPG (mmol/l) − 3.5). Our previous study provides 
information on the methods of laboratory analysis [10].
GDM risk calculations
To evaluate the performance of currently available and 
validated GDM risk scores in clinically distinct groups, we 
tested the risk calculations by van Leeuwen [17] and Teede 
[18]. These two risk scores showed the best performance 
according to a BMJ review [7]. The Van Leeuwen score 
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calculates the probability of GDM using simple clinical 
data as binary variables [17]. The formula used was prob-
ability of GDM = 1/[1 + exp(− β)], in which β is calculated 
as [− 6.1 + (0.83 × non-Caucasian ethnicity) + (0.57 × fam-
ily history of diabetes mellitus) − (0.67 × multipara with-
out history of GDM) + (0.5 × multipara with history of 
GDM) + (0.13 × BMI)]. In the original study, 4% probability 
was the suggested cut-off point.
The risk score by Teede is based on giving points accord-
ing to clinical characteristics: age (< 25 years 0 points, 
25–34 years 1 point, and 35 years or older 2 points), BMI 
(< 29 kg/m2 0 points, 30–34.9 kg/m2 1 point, 35 kg/m2 or 
more 2 points), ethnicity (Anglo-Australian, European or 
other 0 points, Polynesian, Maritime Southeast Asian, Chi-
nese Asian, southern Asian or African 1 point, Mainland 
Southeast Asian 2 points), family history of diabetes (1 
point), and history of GDM (2 points). A score of 4 or more 
was the suggested cut-off point [18].
Statistics
Mean and SD were calculated for continuous variables; 
frequency with percentages was calculated for categorical 
variables. Statistical comparison between groups was made 
by the analysis of variance (ANOVA), Chi-square test, or 
Fisher–Freeman–Halton test. In the case of violation of the 
assumptions (e.g., non-normality), a bootstrap-type ANOVA 
(5000 replications) was used. The bootstrap method is sig-
nificantly helpful when the theoretical distribution of the 
test statistic is unknown or in the case of violation of the 
assumptions. Incidence of GDM was analyzed using gen-
eralizing estimating equation (GEE) models, and 95% 
confidence intervals with exact or maximum likelihood. 
Agreement, a measure of test reliability, was calculated 
by dividing the number of women who tested positive by 
the true number of women with the condition (GDM). All 
analyses were performed using STATA 14.1 (StataCorp LP, 
College Station,TX).
Results
In total, 510 women were included in the analysis. Among 
them, 88 women entered the study before pregnancy and the 
remaining in the first trimester. Total cumulative incidence 
of GDM was 49.4% (95% CI 45.0–53.8) and 37.4% (95% 
CI 33.2–41.8) of all participants were diagnosed in the first 
trimester. When compared to women without GDM, partici-
pants diagnosed with GDM were more often multiparous, 
had a history of GDM (p < 0.001), or a family history of dia-
betes (p < 0.001). There was no difference in pre-pregnancy 
BMI [no-GDM 31.7 kg/m2 (95% CI 31.0–32.4) and GDM 
31.6 kg/m2 (95% CI 30.8–32.4) p = 0.84] or in first trimester 
characteristics such as dietary intake, physical activity, or 
age between women diagnosed with GDM compared with 
those not diagnosed.
In an attempt to characterize “early GDM”—women, we 
compared non-GDM women to women diagnosed either 
in the first or the second trimester. Women diagnosed in 
the first trimester had a higher pre-pregnancy BMI (mean 
Fig. 1  a Histogram showing 
the distribution of estimated 
probability of GDM, calculated 
by the Van Leeuwen risk score. 
The real GDM incidence in 
RADIEL study is shown with 
dotted line. b Histogram show-
ing the distribution of risk score 
points (grey) in the total study 
population, calculated by the 
Teede risk score. The black area 
within each risk score column 
indicates the presence of GDM 
among the RADIEL partici-
pants with that specific score
Estimated probability of GDM
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32.4 kg/m2) both compared with those diagnosed in the 
second trimester (28.9 kg/m2) and the non-GDM group 
(31.7 kg/m2 p < 0.001). There was also a trend towards a 
difference in family history of diabetes (no-GDM 21%, early 
GDM 41% and standard GDM 28%, p = 0.069).
We tested two selected GDM risk scores in our high-risk 
cohort. Figure 1a, b illustrates their performance. Estimated 
mean probability of GDM calculated by van Leeuwen score 
was 19%, which was lower than the real GDM incidence 
49%. The risk score by Teede succeeded in risk identifica-
tion in 61% of cases, with numerous GDM women falling 
below the 4 points’ cut-off limit.
We then divided the high-risk women into groups (A, 
B, C, D) according to their BMI, parity, and history of 
GDM. Table 1 shows the first trimester characteristics of 
these groups, whereas Fig. 2 presents the cumulative GDM 
incidence. When compared to other groups, the non-obese 
women with previous GDM (group C) showed significantly 
better metabolic characteristics in the first trimester. Com-
pared to group A, the risk of GDM was similar in group 
B [OR 0.87 (95% CI 0.51–1.48)] and markedly higher in 
group C [OR 2.52 (95% CI 1.60–3.97)] and group D [OR 
4.96 (95% CI 2.87–8.58)], who both had a history of previ-
ous GDM.
The Van Leeuwen risk score was tested also separately 
in groups A, B, C, and D (Fig. 3). Groups A and D had the 
highest estimated probability of GDM (mean 21% and 31%, 
respectively), and in groups B and C, it was lower (mean 
Table 1  Characteristics of the participants in the first trimester according to ABCD grouping
Values are presented as means (SD) unless otherwise indicated
A, N = 166 B, N = 97 C, N = 148 D, N = 99 p value





Age (years) 31 (5) 33 (5) 33 (4) 33 (5) < 0.001
BMI (kg/m2) 35.3 (4.2) 34.9 (3.6) 24.9 (2.6) 34.9 (4.2) < 0.001
Educational attainment 
(years)
14.4 (2.1) 14.2 (1.9) 14.9 (2.0) 13.7 (2.0) < 0.001
Family history of DM, n 
(%)
42 (25) 20 (22) 51 (35) 35 (37) 0.044
Gestational weeks, median 
(IQR)
13.0 (11.9, 14.4) 13.1 (12.3, 14.6) 12.9 (11.4, 14.0) 13.0 (11.7, 14.4) 0.10
Parity, n (%) 0.013
 0 166 (100) 0 (0) 0 (0) 0 (0)
 1 – 67 (69) 88 (59) 52 (53)
 2 – 22 (23) 45 (30) 25 (25)
 3– – 8 (8) 15 (10) 22 (22)
Smoking, n (%) 9 (5) 5 (5) 4 (3) 4 (4) 0.66
Alcohol use, n (%) 6 (4) 4 (4) 9 (6) 8 (8) 0.40
Physical activity (min/
week)
60 (30, 120) 60 (30, 120) 90 (30, 150) 60 (30, 125) 0.58
Diet (HFII) 9.5 (2.7) 9.6 (2.9) 10.8 (2.7) 10.1 (2.9) < 0.001
Total triglycerides (mmol/l) 1.39 (0.54) 1.36 (0.51) 1.10 (0.37) 1.49 (0.81) < 0.001
Fasting plasma glucose 
(mmol/l)
5.08 (0.44) 4.95 (0.34) 5.06 (0.41) 5.23 (0.40) < 0.001
 1 h—glucose (mmol/l) 7.32 (1.81) 7.07 (1.52) 7.72 (1.77) 7.93 (1.84) < 0.001
 2 h—glucose (mmol/l) 6.19 (1.31) 6.17 (1.18) 6.16 (1.40) 6.51 (1.52) 0.27
LDL cholesterol (mmol/l) 2.72 (0.60) 2.91 (0.81) 2.65 (0.70) 2.86 (0.71) 0.025
Fasting plasma insulin 
(mU/l)
11.13 (8.14) 9.28 (3.78) 5.75 (3.63) 9.83 (5.21) < 0.001
Total cholesterol (mmol/l) 4.78 (0.72) 5.02 (0.92) 4.74 (0.84) 5.01 (0.92) 0.017
hs-CRP (mmol/l) 9.55 (7.18) 8.53 (5.99) 4.29 (3.78) 11.18 (11.35) < 0.001
Adiponectin (mg/ml) 15.8 (6.1) 16.2 (5.3) 18.3 (6.5) 15.2 (5.5) 0.004
HbA1c (%) 5.24 (0.30) 5.27 (0.31) 5.25 (0.28) 5.33 (0.35) 0.18
TNF-alfa (pg/ml) 11.5 (8.9) 10.9 (5.6) 12.1 (9.5) 10.8 (5.1) 0.56
IL-6 (pg/ml) 6.18 (6.80) 5.07 (5.45) 9.27 (14.40) 5.20 (3.40) 0.020
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11%). Figure 4 shows risk scores by Teede in the ABCD 
groups together with the true incidence of GDM. Teede 
score was most successful in risk identification in group B 
(69% agreement) and worst in the non-obese group C (52% 
agreement).
Due to the weak performance of the previous scores, we 
further investigated this high-risk group to find useful risk 
markers taking simultaneously into account the heteroge-
neity of GDM. Among the 319 participants with normal 
glucose tolerance in the first trimester, we analyzed the most 
commonly used risk markers (age, family history of diabe-
tes, fasting glucose,  HbA1c, lipids, and hs-CRP) in the total 
study population and inside the ABCD groups by multiple 
logistic regression model. The supplementary table presents 
the results concerning the total study population. In group 
A, first trimester fasting plasma glucose was associated with 
GDM risk [OR 3.76 (95%CI 1.48–9.53) p = 0.005], but 
this was not seen in the other groups. None of the markers 
showed predictive potential in groups B, C, or D. In predict-
ing GDM, there was no interaction between family history 
of diabetes (p = 0.76) or diet (HFII) (p = 0.70) and allocation 
to ABCD group.
Discussion
The best-rated GDM risk scores seem to underestimate the 
incidence of GDM in high-risk women, even when tested 
in phenotypically distinct groups. Our results demonstrate 
a considerably high incidence of GDM already in the first 
trimester: within this high-risk group with a BMI ≥ 30 kg/m2 
and/or previous GDM, almost half (49%) developed GDM 
and 37% received the diagnosis already in the first trimester. 
In the subgroup of primiparous obese women, fasting glu-
cose was a predictor of GDM, but in the other subgroups, 
there were no identifiable markers. Notably, women with 
previous GDM are at increased risk of GDM already at the 
first trimester; 38% of the non-obese and 63% of the obese 
women with previous GDM received an “early GDM” diag-
nosis. This challenges the development of GDM risk scores 
even further.
There is ongoing debate on the appropriate GDM screen-
ing strategy. Following the HAPO study [19], The Inter-
national Association of the Diabetes and Pregnancy Study 
Groups (IADPSG) published new diagnostic thresholds 
for GDM and in 2013 also WHO endorsed them [20] rec-
ommending universal screening at 24–28 weeks. EBCOG 
(European Board and College of Obstetrics and Gynaecol-
ogy) has raised concern about a universal screening strategy 
in Europe [21], where procedures vary highly. The diagnos-
tic thresholds and the importance of first trimester screening 
are even more controversial. IADPSG recommends [22] a 
fasting glucose cutoff of 5.1 mmol/l and directing the early 
screening towards high-risk women (overweight/obesity, 
previous GDM, family history of diabetes, previous mac-
rosomia, or polycystic ovary syndrome (PCOS), and certain 
ethnicities). Our results support the IADPSG recommen-
dation, since with fasting glucose 5.3 mmol/l as a cutoff, 
among women with either previous GDM or obesity, the 
first trimester incidence of GDM was 37.4%.
One obstacle for universal OGTT screening is naturally 
financial. Furthermore, it is time-consuming and burden-
some requiring overnight fasting. Studies have, therefore, 
aimed at finding predictors of GDM to enable risk-factor-
based screening. BMI has been considered the main risk 
factor for GDM, but a recent study showed that a random 
plasma glucose performed better than age or BMI in early 
pregnancy [23]. Still, with a ≥ 7.5 mmol/l plasma glucose 
cutoff, the sensitivity was only 0.70 and specificity 0.90. 
Results concerning  HbA1c and adiponectin [24–26] have 
not been convincing either. In a retrospective study, the sec-
ond trimester  HbA1c was strongly associated with perinatal 
outcomes, but it was not useful in first trimester screening 
[25] and a prospective study [24] found an association only 
between first trimester  HbA1c and macrosomia.
One approach for identifying women at GDM risk has 
been the development of prognostic models, taking advan-
tage of commonly available clinical data. A systematic 
review in the BMJ [7] validated 12 GDM risk scores. Age, 
BMI, ethnicity, family history of diabetes, history of GDM, 
and history of macrosomia were the most common pre-




































Fig. 2  Cumulative incidence of GDM in the first and second trimester 
according to ABCD groups
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cohort of 3723 women, where only women with risk factors 
or symptoms of GDM underwent an OGTT, based on WHO 
1999 diagnostic guidelines (fasting glucose 7.0 mmol/l and 
2-h glucose 7.8 mmol/l). The C-statistics ranged from 0.67 
to 0.77, and even the best models, Teede (0.77) [18] and Van 
Leeuwen (0.74) [17], performed only moderately. In accord-
ance with our findings, they also demonstrated differences 
in the score performance based on parity [7]. In our study 
cohort, these risk scores underestimated the probability of 
GDM, but especially among the non-obese women with pre-
vious GDM (11% versus 59%). This highlights the difficulty 
of finding normal-weight women at high GDM risk.
Most recent studies have also applied more advanced 
methods for risk identification [27–29]. For example, the 
prediction model derived from the UPBEAT study [29] 
combined clinical data with  HbA1c, glucose, fructosamine, 
triglycerides, adiponectin, and sex hormone-binding globu-
lin (SHBG). This prognostic model for obese women had a 
C-statistic of 0.77 and 50% of score-positive women devel-
oped GDM. This is similar to our results; using BMI ≥ 30 kg/
m2 or previous GDM as risk factors, we identified a group 
with a similar diagnosis rate. In addition, we analyzed other 
markers including inflammatory markers, HOMA-IR, and 
HOMA-ß, but in these subgroups, they were not successful 
in predicting GDM.
Several studies have focused on the heterogeneity of type 
2 diabetes [8, 9] and current practice is tailoring the treat-
ment according to the underlying pathophysiology [30]. 
Although the first studies describing GDM heterogene-
ity date from the 1980s [12, 13], there is still insufficient 
Fig. 3  Histogram showing the 
distribution of estimated prob-
ability of GDM, calculated by 
the Van Leeuwen risk score, 
separately in ABCD groups. 
The real GDM incidence in the 
RADIEL study is shown with 
dotted line
Estimated probability of GDM
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knowledge on varying backgrounds. Damm [12] demon-
strated that obese and non-obese GDM women have dis-
tinct insulin secretion profiles; the non-obese had a lower 
and slower insulin response profile which persisted even 
5–11 year postpartum. According to a recent study, 51% of 
GDM women had primarily a deficiency in insulin sensitiv-
ity, 30% in insulin secretion, and 18% a mixed pathophysiol-
ogy [31]. Elevated cesarean section and macrosomia rates 
were associated only with insulin resistance highlighting the 
importance of the underlying pathophysiology.
We divided the participants of the RADIEL study [14] 
into four groups according to BMI, parity, and GDM history. 
Although the non-obese women had better metabolic health 
and diet scores in early pregnancy, their GDM incidence was 
markedly higher in the second trimester [10]. The previous 
studies have shown a higher occurrence of diabetes-related 
autoantibodies among non-obese women [11], but in the 
RADIEL study, the overall prevalence of autoimmunity was 
low and did not provide an explanation. Together with the 
previous studies, our findings emphasize the marked het-
erogeneity of GDM and elucidate the varying risk profiles 
according to parity and BMI. In this high-risk cohort, the 
potential risk predictors were fasting glucose, HbA1c, and 
family history of diabetes; unfortunately, we failed in find-
ing tools for identifying the non-obese women at high risk.
Strengths of our study are the inclusion of non-obese 
women and measurements of numerous biomarkers. In addi-
tion, in contrast to many other studies, OGTT was performed 
also in the first trimester, and therefore, we have detailed 
information on the glycemic status throughout pregnancy. 
Our population was ethnically homogenous, Caucasian, 
which affects our findings as both scores tested emphasize 
ethnicity, and this also limits the generalizability of our find-
ings. Lack of a control group from the normal population 
or non-obese women without previous GDM can be con-
sidered a weakness. The diagnostic strategy and the OGTT 
thresholds were different in our study compared to those 
used in the development of the current risk scores, which 
might influence our findings. Our diagnostic thresholds, 
however, exceed the current IADPSG recommendations and, 
therefore, fail in finding all women currently defined to have 
GDM. Test performance was evaluated by calculating agree-
ment between the tests, but it should be acknowledged that it 
does not determine performance of the test on an individual 
level. We also recognize the challenges, when testing a risk 
score developed for the general population in a high-risk 
population. Our aim was, however, to investigate the impact 
of GDM heterogeneity on the performance of GDM risk 
scores. In addition, as these risk calculations give an indi-
vidual risk estimate, i.e., a probability of a disease based on 
individual characteristics not depending on the surrounding 
population, this provides a possibility to assess the perfor-
mance of the risk scores also in a high-risk cohort.
In conclusion, we hypothesize that the underlying het-
erogeneity offers an explanation for the difficulties in creat-
ing a GDM risk score. It might be impossible to create a 
universal risk score, but if resources are low and targeting 
the diagnostic tests or preventive measures is needed, our 
simple model using BMI and GDM history detects a risk 
group with a 50% diagnosis rate, a similar performance to 
the previous much more complex models. Based on our 
results, we hypothesize that universal screening, in accord-
ance with WHO and IADPSG guidelines, could be the only 
way to identify non-obese women at high GDM risk in their 
first pregnancy. In the age of personalized medicine [32], the 
heterogeneous background of GDM requires more research 
for better understanding of the pathophysiology, possible 
Fig. 4  Histogram showing the 
distribution of risk score points 
(grey), calculated by the Teede 
risk score, separately in ABCD 
groups. The black area within 
each risk score column indicates 
the presence of GDM among 
the RADIEL participants with 
that specific score
Risk factor score
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methods of treatment, and consequences for the mother and 
child in the future.
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